Molecular targeting of pancreatic disorders
- PMID: 15891936
- DOI: 10.1007/s00268-004-7821-6
Molecular targeting of pancreatic disorders
Abstract
During the last decade significant advances in gene therapy have made it possible to treat various pancreatic disorders in both animal models and in humans. For example, insulin gene delivery to non-beta-cell tissues has been shown to reverse hyperglycemia in diabetic mice, and islet transplantation, based on in vitro differentiation of beta cells and concomitant gene targeting to prevent host autoimmune responses, has become more feasible. Additionally, introduction of the glucokinase regulatory protein and protein kinase C-zeta have been shown to improve glucose tolerance in non-insulin-dependent diabetes mellitus animal models. Pancreatic cancer studies utilize several DNA-based strategies for tumor treatment including introduction of tumor suppressor genes, suppression of oncogenes, suicide gene/prodrug therapy, and restricted replication-competent virus therapy. Tumor-specific targeting is an important part of suicide gene therapy, and tumor-specific promoters are used for cell-specific targeting. Tumor-specific suicide gene therapy directed by the rat insulin promoter has been used to eliminate insulinoma tumors in a mouse model. This review compiles a compendium of information related to the treatment of pancreatic disorders using gene therapy.
Similar articles
-
Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.Hum Gene Ther. 2010 Feb;21(2):157-70. doi: 10.1089/hum.2009.083. Hum Gene Ther. 2010. PMID: 19751100
-
Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy.J Gene Med. 2005 May;7(5):672-80. doi: 10.1002/jgm.701. J Gene Med. 2005. PMID: 15580629
-
Specific targeting of pancreatic islet cells in vivo by insulin-promoter-driven adenoviral conjugated reporter genes.World J Surg. 2006 Aug;30(8):1543-52. doi: 10.1007/s00268-005-0688-3. World J Surg. 2006. PMID: 16855800
-
Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus and pancreatic neuroendocrine tumors.Expert Opin Ther Targets. 2017 Jan;21(1):77-89. doi: 10.1080/14728222.2017.1257000. Epub 2016 Nov 18. Expert Opin Ther Targets. 2017. PMID: 27841034 Review.
-
Gene Therapy for Pancreatic Diseases: Current Status.Int J Mol Sci. 2018 Oct 31;19(11):3415. doi: 10.3390/ijms19113415. Int J Mol Sci. 2018. PMID: 30384450 Free PMC article. Review.
Cited by
-
Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging.Mol Pharm. 2010 Feb 1;7(1):22-31. doi: 10.1021/mp900128x. Mol Pharm. 2010. PMID: 19899813 Free PMC article.
-
Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster.Cancer Sci. 2007 Mar;98(3):455-63. doi: 10.1111/j.1349-7006.2007.00408.x. Epub 2007 Jan 12. Cancer Sci. 2007. PMID: 17233811 Free PMC article.
-
Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.PLoS One. 2012;7(7):e40611. doi: 10.1371/journal.pone.0040611. Epub 2012 Jul 16. PLoS One. 2012. PMID: 22815775 Free PMC article.
-
Growth factor control of pancreatic islet regeneration and function.Pediatr Diabetes. 2009 Feb;10(1):14-32. doi: 10.1111/j.1399-5448.2008.00468.x. Epub 2008 Sep 19. Pediatr Diabetes. 2009. PMID: 18828795 Free PMC article. Review.
-
The immune boundaries for stem cell based therapies: problems and prospective solutions.J Cell Mol Med. 2009 Aug;13(8A):1464-75. doi: 10.1111/j.1582-4934.2009.00837.x. Epub 2009 Jul 6. J Cell Mol Med. 2009. PMID: 19583810 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical